Reviva Pharmaceuticals Holdings (RVPH) Return on Capital Employed (2019 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Return on Capital Employed of 124.31% for Q1 2026, up 51.68% sequentially from 257.25% in Q4 2025, and down 1354433.0% YoY from N/an in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Return on Capital Employed (2019 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Return on Capital Employed for 8 years, with the latest figure at 124.31% in Q1 2026.
- Quarterly Return on Capital Employed fell 1354433.0% year-over-year to 124.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124.31% (down 1354433.0% YoY) and the FY2025 annual result came in at 239.41%, up 37654.0% from the prior year.
- Return on Capital Employed rose to 124.31% in Q1 2026 per RVPH's latest filing, from 257.25% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 13420.02% in Q1 2025 and troughed at 984.8% in Q1 2024.
- A 5-year average of 1738.92% and a median of 123.56% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed surged 1440482 bps in 2025, then tumbled 1354433 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 237.49% in 2022, then surged by 732 bps to 1501.3% in 2023, then sank by 32 bps to 1014.78% in 2024, then tumbled by 125 bps to 257.25% in 2025, then jumped by 52 bps to 124.31% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 124.31%, 257.25%, and 706.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -82.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -82.10% |
| Mar 31, 2026 | -124.31% |
| Dec 31, 2025 | -257.25% |
| Sep 30, 2025 | -706.42% |
| Jun 30, 2025 | 1,005.32% |
| Mar 31, 2025 | 13,420.02% |
| Dec 31, 2024 | 1,014.78% |
| Sep 30, 2024 | 352.16% |
| Jun 30, 2024 | 1,174.85% |
| Mar 31, 2024 | -984.80% |
| Dec 31, 2023 | 1,501.30% |
| Sep 30, 2023 | 445.21% |
| Jun 30, 2023 | 11,983.95% |
| Mar 31, 2023 | -519.09% |
| Dec 31, 2022 | -237.49% |
| Sep 30, 2022 | -140.53% |
| Jun 30, 2022 | -105.05% |
| Sep 30, 2021 | -18.96% |
| Jun 30, 2021 | -22.22% |
| Mar 31, 2021 | -15.40% |